Use the Back button in your browser to see the other results of your search or to select another record.
| Wearable activity trackers to improve physical activity and cardiovascular risk in type 2 diabetes: a randomized pilot study |
| Wu P-T, Baltich AA, Chu IH, Chui KK |
| Diabetology 2025 Sep 8;6(9):97 |
| clinical trial |
| This trial has not yet been rated. |
|
BACKGROUND/OBJECTIVES: Type 2 diabetes (T2D) is associated with elevated cardiovascular risk and mortality. While physical activity can reduce cardiovascular risk, sustaining behavioral change remains challenging. Wearable activity trackers offer a scalable approach to promote physical activity, but their effects on cardiovascular outcomes in adults with T2D have not been well studied. To evaluate the impact of a wrist-worn activity tracker on physical activity, cardiovascular markers, and metabolic outcomes in adults with T2D over four weeks. METHODS: This pilot randomized controlled trial included eight adults with T2D (mean age 54.9 +/- 12.6 years; intervention (FIT) group: n = 5; control (CON) group: n = 3). The intervention group received an activity tracker. Both groups used the Fitbit app to track daily activity. Physical activity metrics (steps, walking distance, energy expenditure) and cardiovascular markers (blood pressure, augmentation index, pulse wave velocity, subendocardial viability ratio (SEVR)) were assessed pre- and post-intervention. Non-parametric tests and Spearman correlations were used due to the small sample size. RESULTS: The FIT group showed significant increases in walking distance and energy expenditure and reductions in systolic/diastolic blood pressure, pulse pressure, and mean arterial pressure (all p < 0.04). SEVR trended toward improvement (p = 0.07). No significant changes were seen in the CON group. Increased physical activity was strongly correlated with reductions in pulse pressure (p = -0.88) and fasting glucose (p = -0.82; both p < 0.05). CONCLUSIONS: A brief wearable-based intervention improved physical activity and cardiovascular markers in adults with T2D, supporting feasibility for diabetes care.
|